Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients

Clinica Chimica Acta

Volumn 401, Issue 1-2, 2009, Pages 144-147

  Chang, Nai Wen ^a   Chen, Fei Na ^a   Wu, Chen Teng ^b   Lin, Chin Fen ^a   Chen, Dar Ren ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b FENG YUAN HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Apolipoprotein E4 allele; Breast cancer; Hypertriglyceridemia; Tamoxifen

Indexed keywords

APOLIPOPROTEIN E4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALLELES; APOLIPOPROTEIN E4; BREAST NEOPLASMS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; TAMOXIFEN; TRIGLYCERIDES;

EID: 58549096553     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.12.005     Document Type: Article

References (20)

1. Benson J.R. Tamoxifen in early breast cancer. Lancet 352 (1998) 404-405
2. Bagdade J.D., Wolter J., Subbaiah P.V., and Ryan W. Effect of tamoxifen treatment on plasma lipids and lipoproteins lipid composition. J Clin Endocrinol Metab 70 (1990) 1132-1135
3. Gupta S., Tandon V.R., Kapoor B., Gupta A., Gupta G.D., and Khajuria V. Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer. J Assoc Phys India 54 (2006) 183-186
4. Liu C.L., and Yang T.L. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 79 (2003) 11-16
5. Koshizuka K., Serizawa M., Hasuda N., et al. Tamoxifen-induced severe hypertriglyceridemia-report of 3 cases. Gan To Kagaku Ryoho 31 (2004) 1109-1112
6. Kusama M., Kaise H., Nakayama S., Ota D., Misaka T., and Aoki T. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations. Breast Cancer Res Treat 88 (2004) 9-16
7. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
8. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988) 622-630
9. Davignon J., Gregg R.E., and Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8 (1988) 1-21
10. Breslow J.L. Genetic basis of lipoprotein disorders. J Clin Invest 84 (1989) 373-380
11. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31 (1990) 545-548
12. Somekawa Y., and Wakabayashi A. Relationship between apolipoprotein E polymorphism, menopausal symptoms, and serum lipids during hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 79 (1998) 185-191
13. Liberopoulos E., Karabina S.A., Tselepis A., et al. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?. Oncology 62 (2002) 115-120
14. Moysich K.B., Freudenheim J.L., Baker J.A., et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog 27 (2000) 2-9
15. Sharma D., Sharma U., Bhatnagar V.B., and Singh V.S. A comparative of the effect of tamoxifen on serum lipid and lipoprotein profile in premenopausal & postmenopausal women with breast carcinoma & associated risk of vascular complication. Indian J Med Sci 55 (2001) 37-42
16. Assmann G., and Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Münster (PROCAM) Study. Eur J Epidemiol 8 Suppl 1 (1992) 99-103
17. Castelli W.P. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 70 (1992) H3-H9
18. Chang N.W., Chen D.R., Wu C.T., et al. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. Breast Cancer Res Treat 90 (2005) 257-261
19. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
20. Berry D.A., Muss H.B., Thor A.D., et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18 (2000) 3471-3479